Medical disclaimer: This guide is for educational purposes only. Vidaya does not sell, prescribe, or recommend peptides. Always consult a licensed healthcare provider before starting any peptide therapy.

Evidence-Based Guide

Peptides: Types, Evidence
& Risks

Not all peptides are equal. Some are FDA-approved medicines backed by large clinical trials. Others have only animal data and zero quality control. This guide grades every major peptide by evidence, regulatory status, and real risks — so you can make informed decisions with your doctor.

How We Grade Evidence

Large RCTs, guideline-supported

Moderate RCTs or strong observational data

Small studies, mostly preclinical

Mechanistic hypothesis only

Grades reflect the quality of clinical evidence for human use, not whether a peptide "works." A grade-C peptide may have compelling animal data but simply hasn't been tested in rigorous human trials yet.

Peptide Categories

Metabolic & Weight Management

GLP-1 receptor agonists and dual agonists — the most evidence-backed peptide category, with large cardiovascular outcome trials and FDA approvals for diabetes and obesity.

Semaglutide

(Ozempic / Wegovy)

Evidence: AFDA-Approved

GLP-1 receptor agonist. Reduces body weight 15–17% in trials. Demonstrated cardiovascular risk reduction (SELECT trial). FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy).

Key Risks

GI side effects (nausea, vomiting, constipation) — #1 reason for discontinuation
Boxed warning: thyroid C-cell tumors in rodents; contraindicated with personal/family history of medullary thyroid carcinoma or MEN2
Gallbladder disease, rare pancreatitis signal
Delayed gastric emptying → aspiration risk under anesthesia
Lean-mass loss without resistance training
May cause fetal harm — contraindicated in pregnancy

Tirzepatide

(Mounjaro / Zepbound)

Evidence: AFDA-Approved

Dual GIP/GLP-1 receptor agonist. Up to 22.5% body weight reduction in trials (SURMOUNT). FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Key Risks

Same GI side-effect profile as semaglutide (nausea, diarrhea, constipation)
Boxed warning: thyroid C-cell tumors in rodents; same MTC/MEN2 contraindication
Acute pancreatitis (rare but FDA-documented)
Hypoglycemia when combined with insulin or sulfonylureas
Lean-mass loss without resistance training

Liraglutide

(Victoza / Saxenda)

Evidence: AFDA-Approved

Earlier GLP-1 agonist. ~8% body weight reduction. First GLP-1 approved for weight management (Saxenda). Cardiovascular benefit in LEADER trial.

Key Risks

Similar GI and thyroid C-cell tumor warnings as semaglutide
Requires daily injection (vs. weekly for semaglutide/tirzepatide)
Pancreatitis, gallbladder events

Tesamorelin

(Egrifta)

Evidence: AFDA-ApprovedWADA Banned

GHRH analog. The only FDA-approved GH-axis peptide — specifically for HIV-associated lipodystrophy (visceral fat reduction).

Key Risks

Injection-site reactions, joint pain, peripheral edema
Elevated IGF-1 — theoretical long-term cancer risk
WADA-banned under S2 (peptide hormones)

Growth Hormone Axis

Secretagogues that stimulate endogenous GH release — either via GHRH receptors or ghrelin receptors. Popular in anti-aging and body-composition optimization, but limited large-trial evidence.

CJC-1295

(with DAC (Drug Affinity Complex))

Evidence: CCompoundedWADA Banned

GHRH analog with ~8-day half-life due to DAC modification. Stimulates pulsatile GH secretion. Widely used in anti-aging clinics.

Key Risks

FDA Category 2 (significant safety risks): immunogenicity from aggregation/impurities
Water retention, joint pain, carpal tunnel–like symptoms
Insulin resistance with prolonged use
Elevated IGF-1 — theoretical cancer risk
WADA-banned at all times

Ipamorelin

Evidence: CCompoundedWADA Banned

Selective GHRP (ghrelin-receptor agonist). Raises GH without significantly elevating cortisol or prolactin — considered the most selective of the GHRPs.

Key Risks

FDA Category 2 (immunogenicity concerns)
Increased appetite, water retention
Limited long-term human safety data
WADA-banned at all times

Sermorelin

Evidence: BCompoundedWADA Banned

GHRH analog. Shorter-acting than CJC-1295. Once prescribed for GH-deficient children (Geref, discontinued). Still used via compounding pharmacies.

Key Risks

Injection-site reactions, facial flushing, headache
May affect glucose metabolism
WADA-banned at all times

GHRP-2 / GHRP-6

Evidence: CCompoundedWADA Banned

Potent ghrelin-receptor agonists. Raise GH effectively but are less selective than ipamorelin — also increase cortisol, prolactin, and appetite.

Key Risks

FDA Category 2: immunogenicity, unnatural amino acids complicate characterization
Reports of increased insulin requirement, infection, pancreatitis (causality not established)
Strong appetite stimulation (especially GHRP-6)
Cortisol and prolactin elevation
WADA-banned at all times

MK-677 (Ibutamoren)

Evidence: BResearch OnlyWADA Banned

Non-peptide oral ghrelin mimetic (often grouped with peptides). Raises GH/IGF-1 for ~24h per dose. Extensively studied but never FDA-approved.

Key Risks

One RCT in elderly hip-fracture patients stopped early for congestive heart failure signal
Increased appetite, water retention, insulin resistance
Elevated fasting glucose and HbA1c
Potential edema in susceptible populations
WADA-banned at all times

Recovery & Healing

Regenerative peptides promoted for injury recovery, gut healing, and tissue repair. Strong animal data but minimal human clinical trials. Regulatory status is actively shifting in 2026.

BPC-157

(Body Protection Compound-157)

Evidence: CCompoundedWADA Banned

15-amino-acid gastric pentadecapeptide. Extensive animal data for tendon, ligament, gut, and nerve repair via angiogenesis and nitric oxide modulation. No FDA-approved human use. Regulatory status evolving: FDA scheduled a July 2026 advisory review for potential 503A inclusion.

Key Risks

No published human RCTs — evidence is almost entirely preclinical
Pro-angiogenesis mechanism theoretically could promote tumor vascularization (unstudied)
Gray-market sourcing: no quality standards for non-compounded products
WADA-banned since 2022 (S0: Non-Approved Substances)
FDA previously placed on Category 2 list; removal pending as of April 2026

TB-500

(Thymosin Beta-4 Fragment)

Evidence: CResearch OnlyWADA Banned

Synthetic fragment of thymosin β4. Studied in animals for wound healing, cardiac repair, and hair growth. Small human case series for skin ulcers and corneal lesions.

Key Risks

Minimal human safety/efficacy data
Same pro-angiogenesis concern as BPC-157
WADA-banned since 2018 (S2: Growth Factors)
Gray-market quality/purity risk

GHK-Cu

(Copper Peptide)

Evidence: CCompounded

Copper-binding tripeptide. Solid evidence for topical skin rejuvenation (wound healing, collagen synthesis). Injectable form is less studied and in a regulatory gray zone.

Key Risks

Topical use well-tolerated; injectable form lacks safety data
Nomination for 503A list withdrawn; PCAC review expected before Feb 2027
Copper accumulation theoretically possible with systemic administration

Immune & Longevity

Peptides targeting immune modulation, cellular repair, and aging pathways. Thymosin alpha-1 is the most evidence-backed; longevity peptides are largely theoretical.

Thymosin Alpha-1

(Zadaxin)

Evidence: BApproved Outside US

Immune-modulating peptide approved in 30+ countries (not the US) for hepatitis B and as an immune adjuvant. Evaluated in severe infections and cancer; pilot COVID-19 studies suggested reduced mortality in critically ill patients.

Key Risks

Generally well-tolerated in published studies
Transient redness at injection site
Not FDA-approved — access in the US is through compounding or clinical trials

Epitalon

(Epithalon / Epithalone)

Evidence: DResearch Only

Synthetic tetrapeptide studied for telomerase activation and pineal gland function. Longevity-community favorite. Evidence is limited to cell culture and small animal studies.

Key Risks

No human clinical trials for longevity claims
Previously on FDA Category 2 list; nominated for PCAC review July 2026
Unknown long-term safety profile

MOTS-c

Evidence: DResearch Only

Mitochondrial-derived peptide. Animal data suggests metabolic benefits (improved insulin sensitivity, exercise mimetic effects). Very early research stage.

Key Risks

Preclinical only — no human efficacy or safety data
Nominated for PCAC review July 2026
Gray-market sourcing risk

FOXO4-DRI

Evidence: DResearch Only

Senolytic peptide designed to disrupt FOXO4–p53 interaction and selectively clear senescent cells. Single mouse study showed improved fitness markers.

Key Risks

One published animal study — extremely early evidence
Mechanism (killing cells) has obvious safety implications if off-target
Not available through any regulated pathway

Cosmetic & Sexual Health

Peptides used for tanning, sexual function, and nootropic effects. PT-141 is the only FDA-approved entry; Melanotan II is one of the highest-risk gray-market peptides.

PT-141 (Bremelanotide)

(Vyleesi)

Evidence: AFDA-Approved

Melanocortin-receptor agonist. FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered via subcutaneous auto-injector.

Key Risks

Nausea (~40% of patients)
Transient blood-pressure increase after injection
Skin hyperpigmentation (especially in darker skin tones)
Not approved for men or for on-demand use

Melanotan II

Evidence: CResearch OnlyWADA Banned

Non-selective melanocortin agonist. Promotes skin tanning and has off-label sexual-function effects. Never FDA-approved. Formal safety warnings issued by UK MHRA, Australian TGA, and FDA.

Key Risks

Published case reports of melanoma arising during use — MHRA and TGA safety warnings
Rapid mole darkening: high risk for individuals with many atypical nevi or fair skin
Priapism, nausea, facial flushing
Gray-market only — no quality standards; contamination risk
WADA-banned

Semax

Evidence: CApproved Outside US

Synthetic ACTH fragment used as a nootropic in Russia. Approved there for cognitive disorders and stroke recovery. Investigated for neuroprotective and anti-inflammatory effects.

Key Risks

Limited Western clinical data
Nominated for PCAC review July 2026 for potential US compounding
May affect cortisol levels through ACTH pathway

Oral & Supplement Peptides

Peptides available as dietary supplements — generally well-studied, well-tolerated, and available without prescription. The 'safe and boring' tier.

Collagen Peptides

Evidence: AFDA-Approved

Hydrolyzed collagen (types I, II, III). Meta-analyses show benefits for skin elasticity, tendon properties, fat-free mass, and joint comfort when combined with exercise (~15 g/day, 8+ weeks). GRAS status.

Key Risks

Very safe; occasional mild GI discomfort
Quality varies by brand — look for third-party testing
Not a complete protein source

Bioactive Whey/Casein Peptides

Evidence: BFDA-Approved

Peptide fractions from dairy proteins with ACE-inhibitory, antimicrobial, and immunomodulatory properties. Used in sports nutrition and functional foods.

Key Risks

Generally well-tolerated
Dairy allergen — not suitable for those with milk allergy
Lactose content varies by product

Creatine Peptides

Evidence: BFDA-Approved

Creatine bonded to amino acids for improved solubility. Creatine monohydrate remains the gold-standard form with the most evidence; peptide-bonded forms are an alternative delivery method.

Key Risks

Extremely well-studied safety profile (as creatine monohydrate)
Mild water retention during loading
Some peptide-bonded forms lack comparative efficacy data vs. monohydrate

The Risks Nobody Talks About

Beyond individual peptide side effects, there are systemic risks that apply across the entire non-FDA-approved peptide market.

Gray-Market Quality Crisis

Independent lab analysis of gray-market peptides found:

~30% contained the wrong amino-acid sequence entirely
Two-thirds fell below 95% purity — the minimum research-grade threshold
Contamination with endotoxins, heavy metals (arsenic at 10× safety limits), and undeclared compounds

Source: Janvier et al., 2018 — analysis of seized polypeptide products on the Belgian market. The FDA has called "research use only" labeling "a ruse to avoid FDA scrutiny" and issued 50+ warning letters in 2024–2025.

The Approval Spectrum

FDA-Approved Drug

Phase III trials, manufacturing standards, post-market surveillance

Compounded (503A/503B)

Legal in certain circumstances, less manufacturing oversight, quality varies by pharmacy

"Research Use Only"

Unregulated, zero quality control, illegal for human use. Not research-grade — just unregulated.

Injection-Specific Risks

Immunogenicity— the FDA's primary concern: peptide aggregation and impurities can trigger immune reactions
Sterility — reconstituting lyophilized peptides at home introduces contamination risk
Injection-site reactions: redness, swelling, induration

Athlete Anti-Doping Bans

Most injectable peptides are prohibited by WADA at all times, both in- and out-of-competition:

S0: BPC-157 (since 2022)
S2: TB-500, tesamorelin, all GH secretagogues (CJC-1295, ipamorelin, GHRP-2/6, MK-677)
NCAA enforces similar prohibitions independently

Athletes subject to any anti-doping testing by WADA, USADA, NCAA, NFL, NBA, MLB, or UFC should not use these substances.

2026 Regulatory Update: FDA Reclassifying Peptides

Last updated June 2026

On April 15, 2026, the FDA announced two significant actions:

Removing 12 peptides from Category 2 ("significant safety risk") of the interim compounding policy. Nominations for these substances were withdrawn by their nominators. This includes several GH-axis peptides and investigational compounds.
Scheduling a PCAC advisory meeting for July 23–24, 2026, to evaluate whether seven peptides should be added to the 503A bulks list — which would allow licensed compounding pharmacies to legally produce them. The peptides under review include: BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and Emideltide (DSIP).

What this means: if the PCAC recommends inclusion and the FDA follows through, these peptides could move from the gray market to regulated compounding — a significant shift in both access and quality control. However, removal from Category 2 does notautomatically place substances on the "may compound" list; there may be an interim period of regulatory uncertainty.

Sources: FDA.gov interim 503A Bulks List (republished April 15, 2026); Frier Levitt FDA Peptide Update; Goodwin Law analysis.

If You're Using Peptides, Track These Biomarkers

Working with a prescriber on peptide therapy? Monitoring the right biomarkers is how you know if it's working — and catch problems early.

IGF-1

GH-axis peptides directly elevate IGF-1 — track to ensure you stay in optimal range, not supraphysiological

Fasting Glucose & HbA1c

GH secretagogues and MK-677 can impair insulin sensitivity; GLP-1s improve it. Track the direction.

CRP & Inflammatory Markers

Recovery peptides (BPC-157) are anti-inflammatory in theory — biomarkers confirm or refute.

Liver & Kidney Panels

Baseline and ongoing monitoring for any injectable peptide protocol.

Body Composition (DEXA)

GLP-1s cause lean-mass loss without resistance training. Track lean mass, not just weight.

HRV & Recovery Metrics

Wearable data (HRV, resting HR, sleep quality) shows real-time effects on recovery and autonomic health.

Vidaya tracks all of these — biomarkers from lab uploads, body composition from DEXA scans, and recovery metrics from your wearables — in one place.

Get Started — $89/year

Frequently Asked Questions

Are peptides safe?

Safety varies dramatically by peptide. FDA-approved peptides like semaglutide and tirzepatide have extensive clinical trial data. Many others (BPC-157, TB-500, CJC-1295) have only animal or small-study evidence. The biggest safety variable is often sourcing — gray-market "research" peptides have been found with wrong compounds, heavy-metal contamination, and no sterility controls. Always work with a licensed healthcare provider.

What is the difference between FDA-approved, compounded, and research peptides?

FDA-approved peptides (e.g., semaglutide, tirzepatide, bremelanotide) have passed rigorous clinical trials. Compounded peptides are mixed by pharmacies under sections 503A/503B — legal in certain circumstances but with less oversight. "Research use only" peptides are unregulated products with no quality standards; the FDA has called this labeling "a ruse" when products are clearly intended for human use.

Are peptides banned in sports?

Most injectable peptides are prohibited by WADA at all times, both in- and out-of-competition. BPC-157 is banned under S0 (Non-Approved Substances) since 2022. TB-500 is banned under S2 (Growth Factors). All growth hormone secretagogues are banned under S2. The NCAA enforces similar prohibitions. Athletes subject to any anti-doping testing should not use these substances.

What biomarkers should I track if using peptides?

Key biomarkers include IGF-1 (for GH peptides), fasting glucose and HbA1c (insulin sensitivity), CRP and inflammatory markers, liver and kidney function panels, lipid panels, and body composition. Wearable metrics like HRV, resting heart rate, and sleep quality help assess peptide effects on recovery and overall health.

Is the FDA changing its stance on compounded peptides?

Yes. In April 2026, the FDA announced it will remove twelve peptides from its Category 2 "significant safety risk" list. The PCAC is scheduled to meet July 23–24, 2026, to evaluate whether BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and Emideltide should be added to the 503A bulks list. This could allow licensed compounding pharmacies to legally produce them — a significant regulatory shift.

Does Vidaya sell or prescribe peptides?

No. Vidaya is a health intelligence and tracking platform. We do not sell, prescribe, or recommend specific peptides. Our platform helps you log peptide protocols and correlate them with your biomarkers, body composition, and wearable data so you and your healthcare provider can make informed decisions.

Track Your Peptide Protocol →

Log peptide protocols alongside your biomarkers and wearable data.

Log Your Peptides →

Record which peptides you're on — dosage, frequency, and notes — with safety information built in.

Medical disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Vidaya does not sell, prescribe, or endorse any peptide therapy. Peptide use should only occur under the supervision of a licensed healthcare provider. Individual results vary; clinical evidence grades reflect the state of published research and are not guarantees of efficacy or safety.

Last reviewed: June 11, 2026. Sources include peer-reviewed publications (MDPI, PMC, Springer), FDA.gov, WADA Prohibited List 2026, and FDA prescribing information.

Vidaya provides health insights for informational purposes only. This is not medical advice. Consult your healthcare provider for medical decisions.

How We Grade Evidence

Large RCTs, guideline-supported

Moderate RCTs or strong observational data

Small studies, mostly preclinical

Mechanistic hypothesis only

Peptide Categories

Metabolic & Weight Management

GLP-1 receptor agonists and dual agonists — the most evidence-backed peptide category, with large cardiovascular outcome trials and FDA approvals for diabetes and obesity.

Semaglutide

(Ozempic / Wegovy)

Evidence: AFDA-Approved

Key Risks

GI side effects (nausea, vomiting, constipation) — #1 reason for discontinuation
Boxed warning: thyroid C-cell tumors in rodents; contraindicated with personal/family history of medullary thyroid carcinoma or MEN2
Gallbladder disease, rare pancreatitis signal
Delayed gastric emptying → aspiration risk under anesthesia
Lean-mass loss without resistance training
May cause fetal harm — contraindicated in pregnancy

Tirzepatide

(Mounjaro / Zepbound)

Evidence: AFDA-Approved

Dual GIP/GLP-1 receptor agonist. Up to 22.5% body weight reduction in trials (SURMOUNT). FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Key Risks

Same GI side-effect profile as semaglutide (nausea, diarrhea, constipation)
Boxed warning: thyroid C-cell tumors in rodents; same MTC/MEN2 contraindication
Acute pancreatitis (rare but FDA-documented)
Hypoglycemia when combined with insulin or sulfonylureas
Lean-mass loss without resistance training

Liraglutide

(Victoza / Saxenda)

Evidence: AFDA-Approved

Earlier GLP-1 agonist. ~8% body weight reduction. First GLP-1 approved for weight management (Saxenda). Cardiovascular benefit in LEADER trial.

Key Risks

Similar GI and thyroid C-cell tumor warnings as semaglutide
Requires daily injection (vs. weekly for semaglutide/tirzepatide)
Pancreatitis, gallbladder events

Tesamorelin

(Egrifta)

Evidence: AFDA-ApprovedWADA Banned

GHRH analog. The only FDA-approved GH-axis peptide — specifically for HIV-associated lipodystrophy (visceral fat reduction).

Key Risks

Injection-site reactions, joint pain, peripheral edema
Elevated IGF-1 — theoretical long-term cancer risk
WADA-banned under S2 (peptide hormones)

Growth Hormone Axis

Secretagogues that stimulate endogenous GH release — either via GHRH receptors or ghrelin receptors. Popular in anti-aging and body-composition optimization, but limited large-trial evidence.

CJC-1295

(with DAC (Drug Affinity Complex))

Evidence: CCompoundedWADA Banned

GHRH analog with ~8-day half-life due to DAC modification. Stimulates pulsatile GH secretion. Widely used in anti-aging clinics.

Key Risks

FDA Category 2 (significant safety risks): immunogenicity from aggregation/impurities
Water retention, joint pain, carpal tunnel–like symptoms
Insulin resistance with prolonged use
Elevated IGF-1 — theoretical cancer risk
WADA-banned at all times

Ipamorelin

Evidence: CCompoundedWADA Banned

Selective GHRP (ghrelin-receptor agonist). Raises GH without significantly elevating cortisol or prolactin — considered the most selective of the GHRPs.

Key Risks

FDA Category 2 (immunogenicity concerns)
Increased appetite, water retention
Limited long-term human safety data
WADA-banned at all times

Sermorelin

Evidence: BCompoundedWADA Banned

GHRH analog. Shorter-acting than CJC-1295. Once prescribed for GH-deficient children (Geref, discontinued). Still used via compounding pharmacies.

Key Risks

Injection-site reactions, facial flushing, headache
May affect glucose metabolism
WADA-banned at all times

GHRP-2 / GHRP-6

Evidence: CCompoundedWADA Banned

Potent ghrelin-receptor agonists. Raise GH effectively but are less selective than ipamorelin — also increase cortisol, prolactin, and appetite.

Key Risks

FDA Category 2: immunogenicity, unnatural amino acids complicate characterization
Reports of increased insulin requirement, infection, pancreatitis (causality not established)
Strong appetite stimulation (especially GHRP-6)
Cortisol and prolactin elevation
WADA-banned at all times

MK-677 (Ibutamoren)

Evidence: BResearch OnlyWADA Banned

Non-peptide oral ghrelin mimetic (often grouped with peptides). Raises GH/IGF-1 for ~24h per dose. Extensively studied but never FDA-approved.

Key Risks

One RCT in elderly hip-fracture patients stopped early for congestive heart failure signal
Increased appetite, water retention, insulin resistance
Elevated fasting glucose and HbA1c
Potential edema in susceptible populations
WADA-banned at all times

Recovery & Healing

Regenerative peptides promoted for injury recovery, gut healing, and tissue repair. Strong animal data but minimal human clinical trials. Regulatory status is actively shifting in 2026.

BPC-157

(Body Protection Compound-157)

Evidence: CCompoundedWADA Banned

Key Risks

No published human RCTs — evidence is almost entirely preclinical
Pro-angiogenesis mechanism theoretically could promote tumor vascularization (unstudied)
Gray-market sourcing: no quality standards for non-compounded products
WADA-banned since 2022 (S0: Non-Approved Substances)
FDA previously placed on Category 2 list; removal pending as of April 2026

TB-500

(Thymosin Beta-4 Fragment)

Evidence: CResearch OnlyWADA Banned

Synthetic fragment of thymosin β4. Studied in animals for wound healing, cardiac repair, and hair growth. Small human case series for skin ulcers and corneal lesions.

Key Risks

Minimal human safety/efficacy data
Same pro-angiogenesis concern as BPC-157
WADA-banned since 2018 (S2: Growth Factors)
Gray-market quality/purity risk

GHK-Cu

(Copper Peptide)

Evidence: CCompounded

Copper-binding tripeptide. Solid evidence for topical skin rejuvenation (wound healing, collagen synthesis). Injectable form is less studied and in a regulatory gray zone.

Key Risks

Topical use well-tolerated; injectable form lacks safety data
Nomination for 503A list withdrawn; PCAC review expected before Feb 2027
Copper accumulation theoretically possible with systemic administration

Immune & Longevity

Peptides targeting immune modulation, cellular repair, and aging pathways. Thymosin alpha-1 is the most evidence-backed; longevity peptides are largely theoretical.

Thymosin Alpha-1

(Zadaxin)

Evidence: BApproved Outside US

Key Risks

Generally well-tolerated in published studies
Transient redness at injection site
Not FDA-approved — access in the US is through compounding or clinical trials

Epitalon

(Epithalon / Epithalone)

Evidence: DResearch Only

Synthetic tetrapeptide studied for telomerase activation and pineal gland function. Longevity-community favorite. Evidence is limited to cell culture and small animal studies.

Key Risks

No human clinical trials for longevity claims
Previously on FDA Category 2 list; nominated for PCAC review July 2026
Unknown long-term safety profile

MOTS-c

Evidence: DResearch Only

Mitochondrial-derived peptide. Animal data suggests metabolic benefits (improved insulin sensitivity, exercise mimetic effects). Very early research stage.

Key Risks

Preclinical only — no human efficacy or safety data
Nominated for PCAC review July 2026
Gray-market sourcing risk

FOXO4-DRI

Evidence: DResearch Only

Senolytic peptide designed to disrupt FOXO4–p53 interaction and selectively clear senescent cells. Single mouse study showed improved fitness markers.

Key Risks

One published animal study — extremely early evidence
Mechanism (killing cells) has obvious safety implications if off-target
Not available through any regulated pathway

Cosmetic & Sexual Health

Peptides used for tanning, sexual function, and nootropic effects. PT-141 is the only FDA-approved entry; Melanotan II is one of the highest-risk gray-market peptides.

PT-141 (Bremelanotide)

(Vyleesi)

Evidence: AFDA-Approved

Melanocortin-receptor agonist. FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered via subcutaneous auto-injector.

Key Risks

Nausea (~40% of patients)
Transient blood-pressure increase after injection
Skin hyperpigmentation (especially in darker skin tones)
Not approved for men or for on-demand use

Melanotan II

Evidence: CResearch OnlyWADA Banned

Non-selective melanocortin agonist. Promotes skin tanning and has off-label sexual-function effects. Never FDA-approved. Formal safety warnings issued by UK MHRA, Australian TGA, and FDA.

Key Risks

Published case reports of melanoma arising during use — MHRA and TGA safety warnings
Rapid mole darkening: high risk for individuals with many atypical nevi or fair skin
Priapism, nausea, facial flushing
Gray-market only — no quality standards; contamination risk
WADA-banned

Semax

Evidence: CApproved Outside US

Synthetic ACTH fragment used as a nootropic in Russia. Approved there for cognitive disorders and stroke recovery. Investigated for neuroprotective and anti-inflammatory effects.

Key Risks

Limited Western clinical data
Nominated for PCAC review July 2026 for potential US compounding
May affect cortisol levels through ACTH pathway

Oral & Supplement Peptides

Peptides available as dietary supplements — generally well-studied, well-tolerated, and available without prescription. The 'safe and boring' tier.

Collagen Peptides

Evidence: AFDA-Approved

Key Risks

Very safe; occasional mild GI discomfort
Quality varies by brand — look for third-party testing
Not a complete protein source

Bioactive Whey/Casein Peptides

Evidence: BFDA-Approved

Peptide fractions from dairy proteins with ACE-inhibitory, antimicrobial, and immunomodulatory properties. Used in sports nutrition and functional foods.

Key Risks

Generally well-tolerated
Dairy allergen — not suitable for those with milk allergy
Lactose content varies by product

Creatine Peptides

Evidence: BFDA-Approved

Creatine bonded to amino acids for improved solubility. Creatine monohydrate remains the gold-standard form with the most evidence; peptide-bonded forms are an alternative delivery method.

Key Risks

Extremely well-studied safety profile (as creatine monohydrate)
Mild water retention during loading
Some peptide-bonded forms lack comparative efficacy data vs. monohydrate

If You're Using Peptides, Track These Biomarkers

Working with a prescriber on peptide therapy? Monitoring the right biomarkers is how you know if it's working — and catch problems early.

IGF-1

GH-axis peptides directly elevate IGF-1 — track to ensure you stay in optimal range, not supraphysiological

Fasting Glucose & HbA1c

GH secretagogues and MK-677 can impair insulin sensitivity; GLP-1s improve it. Track the direction.

CRP & Inflammatory Markers

Recovery peptides (BPC-157) are anti-inflammatory in theory — biomarkers confirm or refute.

Liver & Kidney Panels

Baseline and ongoing monitoring for any injectable peptide protocol.

Body Composition (DEXA)

GLP-1s cause lean-mass loss without resistance training. Track lean mass, not just weight.

HRV & Recovery Metrics

Wearable data (HRV, resting HR, sleep quality) shows real-time effects on recovery and autonomic health.

Vidaya tracks all of these — biomarkers from lab uploads, body composition from DEXA scans, and recovery metrics from your wearables — in one place.

Get Started — $89/year

Frequently Asked Questions

Peptides: Types, Evidence& Risks

How We Grade Evidence

Peptide Categories

Metabolic & Weight Management

Semaglutide

Tirzepatide

Liraglutide

Tesamorelin

Growth Hormone Axis

CJC-1295

Ipamorelin

Sermorelin

GHRP-2 / GHRP-6

MK-677 (Ibutamoren)

Recovery & Healing

BPC-157

TB-500

GHK-Cu

Immune & Longevity

Thymosin Alpha-1

Epitalon

MOTS-c

FOXO4-DRI

Cosmetic & Sexual Health

PT-141 (Bremelanotide)

Melanotan II

Semax

Oral & Supplement Peptides

Collagen Peptides

Bioactive Whey/Casein Peptides

Creatine Peptides

The Risks Nobody Talks About

Gray-Market Quality Crisis

The Approval Spectrum

Injection-Specific Risks

Athlete Anti-Doping Bans

2026 Regulatory Update: FDA Reclassifying Peptides

If You're Using Peptides, Track These Biomarkers

Frequently Asked Questions

Are peptides safe?

What is the difference between FDA-approved, compounded, and research peptides?

Are peptides banned in sports?

What biomarkers should I track if using peptides?

Is the FDA changing its stance on compounded peptides?

Does Vidaya sell or prescribe peptides?

Track Your Peptide Protocol →

Log Your Peptides →

Peptides: Types, Evidence& Risks

How We Grade Evidence

Peptide Categories

Metabolic & Weight Management

Semaglutide

Tirzepatide

Liraglutide

Tesamorelin

Growth Hormone Axis

CJC-1295

Ipamorelin

Sermorelin

GHRP-2 / GHRP-6

MK-677 (Ibutamoren)

Recovery & Healing

BPC-157

TB-500

GHK-Cu

Immune & Longevity

Thymosin Alpha-1

Epitalon

MOTS-c

FOXO4-DRI

Cosmetic & Sexual Health

PT-141 (Bremelanotide)

Melanotan II

Semax

Oral & Supplement Peptides

Collagen Peptides

Bioactive Whey/Casein Peptides

Creatine Peptides

The Risks Nobody Talks About

Gray-Market Quality Crisis

Peptides: Types, Evidence
& Risks

Peptides: Types, Evidence
& Risks